Erythromycin Estolate for Oral Suspension USP

Erythromycin Estolate for Oral Suspension USP

Generic Name:
Erythromycin Estolate for Oral Suspension USP
Therapeutic Category:
Antibacterial / Macrolide Antibiotic
Mechanism of Action:
Primarily bacteriostatic action. Erythromycin penetrates the bacterial cell membrane and reversibly binds to the 50S ribosomal subunit of susceptible microorganisms. This action blocks transpeptidation and translocation, effectively inhibiting RNA-dependent protein synthesis and arresting cellular growth. The estolate salt form is uniquely acid-stable, allowing it to pass through gastric acid with less degradation compared to erythromycin base, leading to reliable absorption.

Indications (Therapeutic Uses)

Erythromycin Estolate Oral Suspension is primarily utilized in pediatric and adult populations who prefer liquid formulations for treating mild-to-moderate infections caused by susceptible strains of microorganisms:

  • Upper Respiratory Tract Infections: Treatment of streptococcal pharyngitis (strep throat), tonsillitis, and acute otitis media (middle ear infections).
  • Lower Respiratory Tract Infections: Management of bronchitis and community-acquired atypical pneumonia caused by Mycoplasma pneumoniae or Chlamydia pneumoniae.
  • Pertussis (Whooping Cough): Effective in eradicating Bordetella pertussis from the nasopharynx, helping to shorten the infectious period.
  • Skin and Soft Tissue Infections: Treatment of superficial pyogenic skin infections, impetigo, and erythrasma caused by susceptible staphylococci or streptococci.
  • Diphtheria & Erythrasma: Used as an adjunct to antitoxin for the prevention of a carrier state in diphtheria.

Dosage & Administration

Website Note: The dosage framework, concentration (commonly 125 mg / 5 mL or 250 mg / 5 mL), and duration of treatment must be strictly prescribed by a registered medical practitioner. The complete therapeutic cycle must be finished to prevent the development of bacterial resistance.

  • Standard Pediatric Dose: Calculated based on body weight, typically ranging from 30 mg/kg to 50 mg/kg per day, divided into equally spaced doses (every 6 or 12 hours) depending on the severity of the infection.
  • Standard Adult Dose: When used in adults, the typical dose ranges from 250 mg to 500 mg every 6 hours, or 500 mg to 1,000 mg every 12 hours.
  • Reconstitution Method (For Dry Powder Formulations):
    1. Tap the bottle to loosen the dry powder inside.
    2. Add boiled and cooled water up to approximately half of the fill line marked on the bottle.
    3. Close the cap tightly and shake vigorously to disperse the powder.
    4. Top off with water exactly up to the fill mark line and shake well again until a smooth, uniform suspension is formed.
  • Administration Method: Shake the bottle thoroughly before every single dose to ensure the active drug is evenly distributed. Measure using a calibrated oral dosing syringe or medicine cup.
  • Timing: Unlike some other erythromycin forms, erythromycin estolate is well-absorbed whether taken with or without food. Taking it with a meal can help reduce potential gastrointestinal upset.

Contraindications & Precautions

  • Absolute Contraindications: Completely contraindicated in individuals with a verified history of hypersensitivity to erythromycin, other macrolide antibiotics (e.g., azithromycin, clarithromycin), or any inactive ingredients in the suspension.
  • Hepatic Dysfunction Warning: Erythromycin estolate is associated with a higher risk of cholestatic hepatitis compared to other salts of erythromycin. Symptoms typically include abdominal cramps, nausea, vomiting, followed by jaundice and fever. It is strictly contraindicated in patients with pre-existing hepatic disease or a history of liver dysfunction associated with prior erythromycin use.
  • Critical Drug Interactions (QT Prolongation): Erythromycin is a potent inhibitor of the hepatic CYP3A4 enzyme system. Co-administration is strictly contraindicated with drugs that prolong the QT interval and are metabolized by CYP3A4 (such as cisapride, pimozide, astemizole, and certain antiarrhythmics like quinidine) due to the risk of life-threatening ventricular arrhythmias (Torsades de Pointes).
  • Clostridium difficile-Associated Diarrhea (CDAD): Like most antibiotics, treatment alters the normal microbial flora of the colon, which can trigger an overgrowth of C. difficile. Discontinue therapy immediately if severe, watery, or bloody diarrhea accompanied by intense abdominal cramping develops.
  • Infantile Hypertrophic Pyloric Stenosis (IHPS): Use in neonates has been associated with infantile hypertrophic pyloric stenosis. Parents should be advised to contact their physician if vomiting or irritability occurs during feeding.

Potential Side Effects

  • Common / Mild: Gastrointestinal distress (abdominal localized cramping, nausea, vomiting, diarrhea), temporary loss of appetite, headache, and mild skin rash.
  • Less Common / Severe: Cholestatic jaundice/hepatotoxicity (yellowing of the skin or eyes, dark urine, severe upper abdominal pain), anaphylaxis, prolonged QT interval triggering cardiac arrhythmias, hearing loss or tinnitus (reversible, usually occurring with high doses), and severe C. difficile colitis.